Pilot study explores imepitoin for cats stressed by vet visits: full analysis

A newly published pilot study is putting imepitoin on the radar as a possible option for cats that struggle with the stress of veterinary visits, but the evidence is still preliminary. The Veterinary Sciences paper, published April 28, 2026, randomized 32 cats to receive either imepitoin or placebo before evaluation of physiologic and behavioral stress markers tied to a clinic visit. The headline finding: cats in the imepitoin group had a greater reduction in heart rate and a significant decrease in salivary cortisol, while behavioral scores also moved in a favorable direction. Still, the authors were explicit that the study’s open-label design and assessment methods limit how much weight clinicians should put on those results. (mdpi.com)

That caution matters because feline visit-related stress is already a well-recognized clinical and welfare issue. Cat-friendly guidance from AAFP and ISFM has long framed the problem as more than a handling challenge inside the exam room. Stress often starts at home with the carrier, builds during transport, and compounds in the waiting room and during restraint. Those guidelines recommend preparing cats ahead of visits, reducing stressors in the clinic environment, and using the least invasive handling possible. (pmc.ncbi.nlm.nih.gov)

Against that backdrop, the new study is best understood as an exploratory attempt to test whether imepitoin’s known pharmacology might translate into a feline pre-visit stress tool. According to the article abstract, cats were randomly assigned to imepitoin or placebo, with 16 cats in each group, and assessed using heart rate, respiratory rate, rectal temperature, salivary cortisol, and behavioral scoring systems including the Cat Stress Score and Cat Examination Response Scale. The authors reported a larger pre- to post-treatment heart-rate reduction with imepitoin than placebo, a differential cortisol change favoring imepitoin, and improved behavioral scores in treated cats. Respiratory rate decreased and rectal temperature increased slightly over time regardless of treatment. (mdpi.com)

The study also sits on a limited but relevant imepitoin literature base in cats. Earlier research in BMC Veterinary Research found imepitoin was generally well tolerated in healthy and epileptic cats, with no serious adverse events reported in the cited work, although that line of research focused on seizure management rather than visit-related stress. In dogs, imepitoin has also been studied for fear- and anxiety-related problems and is marketed in some regions as Pexion. That broader background helps explain why investigators are exploring whether the drug could have a role beyond neurology. (bmcvetres.biomedcentral.com)

Even so, there are reasons to be careful. The authors themselves flagged the biggest one: observer bias. Because the trial was open-label and a single investigator handled both treatment administration and outcome assessment, the behavioral improvements are especially vulnerable to bias. The small sample size also makes the study more hypothesis-generating than definitive. And while the physiologic signals are interesting, they don’t yet answer the practical questions clinicians will ask next, including ideal timing, dose consistency across body sizes and temperaments, adverse-event rates in real-world patients, and how imepitoin would compare head-to-head with other pre-visit options. (mdpi.com)

That comparison point is important because the feline pre-visit medication landscape is not empty. A 2023 clinical field study published in Animals reported that a single oral dose of pregabalin alleviated anxiety and fear in cats during transportation and veterinary visits. In other words, imepitoin would be entering a space where at least one other pharmacologic approach already has published field data. For veterinary professionals, that means this new paper is less a signal to change protocols now and more a sign that the evidence base for feline pre-visit anxiolysis is broadening. (mdpi.com)

Why it matters: For practices trying to improve feline access to care, any intervention that safely lowers stress could have outsized effects on compliance, staff safety, exam quality, and the willingness of pet parents to return. But this study also reinforces a familiar lesson: medication should be evaluated as one layer of a larger cat-friendly system, not as a standalone fix. The strongest current takeaway is that imepitoin may warrant further study, while established environmental preparation, respectful handling, and individualized pre-visit planning remain the standard foundation. (pmc.ncbi.nlm.nih.gov)

What to watch: The next meaningful step will be a larger, blinded, controlled trial that can better separate true drug effect from handling and observer effects, define a practical dosing window, and show whether imepitoin offers a meaningful advantage, or a useful alternative, within feline stress-management protocols. (mdpi.com)